Zinc Carnosine

Decades of real clinical use for the stomach and gut lining specifically

Long clinical history in Japan

Multiple positive human RCTs

Important: These statements have not been evaluated by the FDA. This information is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician before starting any supplement.

Overview

Zinc carnosine (also known clinically as polaprezinc) is a chelated compound combining zinc with the amino acid L-carnosine. Unlike standalone zinc supplements, which are absorbed and distributed throughout the body, this chelated form adheres directly to the stomach and intestinal lining, allowing it to act locally where the mucosal tissue actually needs support.

It's been used clinically in Japan since the 1990s -- long enough to accumulate a genuinely substantial randomized controlled trial base for gastric ulcers, and more recently, for protecting the gut lining from NSAID- and aspirin-related damage. That combination of a long clinical track record and a specific, targeted mechanism is unusual for a mineral-based supplement.

Potential Benefits

Gastric Ulcer Healing

A multicenter randomized, double-blind trial in 258 patients with confirmed gastric ulcers found zinc carnosine produced marked symptom improvement in 75% of patients and a favorable endoscopic healing rate over 8 weeks, performing comparably to a standard mucosal-protective medication.

NSAID & Aspirin Gut Protection

A pilot randomized controlled trial using capsule endoscopy found zinc carnosine significantly reduced small-bowel erosions and ulcers in patients on long-term low-dose aspirin, a real, imaged reduction in gut damage rather than a symptom-only outcome.

H. Pylori Support

A systematic review and meta-analysis of randomized controlled trials found adding zinc carnosine to standard triple therapy improved H. pylori eradication outcomes and safety compared to standard therapy alone.

Tight Junction & Barrier Support

Mechanistically, zinc carnosine is thought to help protect intercellular tight junctions in the gut lining, act as a local antioxidant, and reduce apoptosis in mucosal cells -- the proposed basis for its broad gut-protective effects.

Typical Dosage

Standard Daily Dose

75mg twice daily

Providing roughly 150mg zinc carnosine/day -- the dose used across most clinical trials

What to Look For on the Label

Zinc L-carnosine or polaprezinc

Not the same as generic zinc citrate, glycinate, or picolinate

Pro Tips

Take on an empty stomach or between meals so it can adhere to the gut lining rather than binding food
Give it the full 8-week window used in the ulcer-healing trials before judging results
A reasonable addition alongside long-term NSAID or low-dose aspirin use -- discuss with your doctor first
Counts toward total daily zinc intake -- account for it if also taking a separate zinc supplement

Research Snapshot

A pilot randomized controlled study using capsule endoscopy in patients on long-term low-dose aspirin found that 4 weeks of polaprezinc (150mg/day) significantly reduced the number of small-bowel reddened lesions and erosions/ulcers compared to controls, who showed no significant change. Separately, a 2022 systematic review and meta-analysis of randomized controlled trials found that adding polaprezinc-based therapy to standard antibiotic regimens improved H. pylori eradication rates and safety outcomes compared to standard triple therapy alone.

Source: Watari et al., BMC Gastroenterology (2013)

How Zinc Carnosine Compares

Ingredient	Best For	Key Difference
Zinc Carnosine	Gastric Ulcers, NSAID Gut Protection	Local, gut-lining-adherent action; decades of clinical RCT use
General Zinc	Immune Function, Wound Healing	Systemically absorbed; not targeted to the gut lining
DGL (Licorice)	Heartburn, Stomach Lining	Increases mucus production rather than direct barrier action
L-Glutamine	Gut Barrier, Intestinal Lining	Amino acid fuel source for gut cells, different mechanism

These are the most common comparisons our customers ask about in-store.

Popular Stacks with Zinc Carnosine

Gut Lining Repair

Zinc Carnosine + L-Glutamine + DGL

Multi-pathway gut barrier support

NSAID Protection

Zinc Carnosine + Probiotics + Omega-3

For those on regular NSAID or aspirin use

Gut Microbiome Support

Zinc Carnosine + Akkermansia + Fiber

Combines gut lining and microbiome-focused support

Frequently Asked Questions

How is zinc carnosine different from regular zinc?

Zinc carnosine is a chelated compound (also called polaprezinc) combining zinc with the amino acid L-carnosine, which allows the compound to adhere directly to the stomach and intestinal lining rather than being rapidly absorbed like standalone zinc. That local, gut-lining-specific action is why it's studied separately from general zinc supplementation.

Does zinc carnosine actually help with gastric ulcers?

Yes, with real randomized controlled trial support -- it's been used clinically in Japan for decades under the name polaprezinc. Trials have shown meaningful symptom improvement and endoscopic healing rates in gastric ulcer patients, performing comparably to established mucosal-protective medications.

Can zinc carnosine help with NSAID or aspirin-related gut damage?

There's promising randomized controlled trial evidence specifically for this. A pilot study using capsule endoscopy found zinc carnosine (polaprezinc) significantly reduced small-bowel lesions in patients on long-term low-dose aspirin therapy compared to controls -- a real, imaged outcome, not just a symptom survey.

Sources & References

1. Watari, I., Oka, S., Tanaka, S., et al. (2013). Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study. BMC Gastroenterology, 13, 108.

2. Mahmoud, A., Abuelazm, M., Ahmed, A.A.S., Abdalshafy, H., Abdelazeem, B., & Brašić, J.R. (2022). Efficacy and Safety of Polaprezinc-Based Therapy versus the Standard Triple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 14(19), 4126.

3. Miyoshi, A., Namiki, A., Asagi, S., Harasawa, S., Ooshiba, S., & Hayakawa, K. (1992). Clinical Evaluation of Z-103 on Gastric Ulcer -- A Multicenter Double-Blind Comparative Study with Cetraxate Hydrochloride. Japanese Pharmacology and Therapeutics, 20, 199–223.

All references are peer-reviewed studies or position stands from reputable organizations.